MedPath

Tixagevimab

Generic Name
Tixagevimab
Drug Type
Biotech
CAS Number
2420564-02-7
Unique Ingredient Identifier
F0LZ415Z3B
Background

SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction reduce viral load and improve clinical symptoms of infection. Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. As the RBD binding site of tixagevimab does not overlap with that of cilgavimab, the two can be administered to synergistically impair SARS-CoV-2 infection in individuals who may be exposed to the virus.

Tixagevimab is not approved for any indication by the FDA. Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). EVUSHELD was granted marketing authorization by the EMA on March 28, 2022, and was approved in Canada soon after, on April 14, 2022.

In October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19 when exposed to SARS-CoV-2 variants not neutralized by EVUSHELD. Certain SARS-CoV-2 Omicron subvariants may be associated with resistance to monoclonal antibodies, such as EVUSHELD. The FDA and Health Canada advise healthcare providers to inform patients of this risk.

Indication

Tixagevimab has been issued an emergency use authorization (EUA) by the FDA, in combination with cilgavimab, for the pre-exposure prophylaxis of COVID-19 in adult and pediatric patients aged 12 years and older weighing at least 40 kg. Furthermore, patients must not be currently infected with SARS-CoV-2 or have had known exposure to an individual infected with SARS-CoV-2 and must either be immunocompromised due to a medical condition, medication, or treatment or be otherwise ineligible for vaccination with any eligible COVID-19 vaccine due to a history of severe adverse reactions.

In the US, the combination of tixagevimab and cilgavimab is not authorized for the treatment or post-exposure prophylaxis of COVID-19 and is not a substitute for COVID-19 vaccination. Individuals receiving therapy following COVID-19 vaccination should wait at least two weeks.

In Europe and Canada, cilgavimab in combination with tixagevimab is an approved pre-exposure prophylaxis therapy for COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.

Associated Conditions
Coronavirus Disease 2019 (COVID‑19)
Associated Therapies
Pre-Exposure Prophylaxis (PrEP)
Clinical Trials
Related News

INOVIO's DNA-Encoded Monoclonal Antibodies Show Durable 72-Week Expression Without Immune Rejection in COVID-19 Trial

• INOVIO's Phase 1 trial demonstrates DNA-encoded monoclonal antibodies (DMAbs) maintained stable levels for 72 weeks in all participants, potentially overcoming the short half-life limitations of traditional antibody therapies. • The study showed no anti-drug antibody formation across approximately 1,000 blood samples, a significant advantage over other gene-based delivery approaches where immune rejection has been problematic. • Researchers believe this breakthrough technology could transform treatment approaches for infectious diseases, cancer, and metabolic disorders by enabling sustained therapeutic protein delivery without requiring repeated administration.

AZ's Antibody First to Be Cleared by FDA for COVID Prevention

AstraZeneca's antibody cocktail, Evusheld, has been authorized by the FDA for COVID-19 prevention in individuals with compromised immunity, marking a significant advancement in the fight against the pandemic.

FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV

• The FDA has revoked the Emergency Use Authorization (EUA) for AstraZeneca's Evusheld due to the expiration of all distributed lots and high prevalence of non-susceptible variants. • Regeneron requested the FDA revoke the EUA for REGEN-COV because all manufactured lots have expired, and the company no longer intends to offer the product in the United States. • Both Evusheld and REGEN-COV were not authorized for use in any region of the U.S. at the time of the requests due to the high frequency of circulating SARS-CoV-2 variants that are non-susceptible to these treatments. • The FDA determined that revoking these authorizations is appropriate to protect public health and safety, given the reduced efficacy against current variants.

FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products

• The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody products used in the U.S. government's COVID-19 response. • The revoked EUAs include treatments from Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron Pharmaceuticals due to the rise of resistant SARS-CoV-2 variants. • These monoclonal antibody products have not been authorized for patient administration for over a year because of ineffective against current variants. • Healthcare facilities will receive instructions from the sponsors for the return and disposal of the revoked products.

FDA Revokes Emergency Use Authorizations for Four Monoclonal Antibody Treatments Due to Variant Resistance

• The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody (mAb) products previously used to treat COVID-19 due to persistent resistance from circulating SARS-CoV-2 variants. • These mAbs have not been authorized for patient administration for over a year because of the high prevalence of SARS-CoV-2 variants against which they are ineffective. • The decision follows previous FDA announcements limiting the EUAs, allowing facilities to retain inventory in anticipation of potential changes in variant susceptibility, which did not occur. • With the expiration of the shelf life for nearly all lots of these products, the FDA has formally revoked the EUAs.

FDA Restricts Emergency Use Authorization for AstraZeneca's Evusheld in the US

• The FDA has restricted the emergency use authorization for AstraZeneca's Evusheld in the US due to the prevalence of resistant SARS-CoV-2 variants. • Evusheld is not currently authorized for pre-exposure prophylaxis of COVID-19 in the US until the prevalence of resistant variants decreases. • AstraZeneca is developing a next-generation long-acting antibody that neutralizes all tested SARS-CoV-2 variants, with potential availability in late 2023. • The US government recommends retaining and properly storing all Evusheld product in case susceptible variants become more prevalent in the future.

FDA Authorizes AstraZeneca's Evusheld for COVID-19 Prevention in Immunocompromised Individuals

• The FDA has granted emergency use authorization for AstraZeneca's Evusheld as a pre-exposure prophylaxis against COVID-19 in specific populations. • Evusheld is intended for adults and adolescents (12 years and older) who are not eligible for COVID-19 vaccination due to medical contraindications. • The authorization is based on clinical trial data showing a 77% reduction in the risk of developing COVID-19 with Evusheld treatment. • Evusheld, a combination of tixagevimab and cilgavimab, is administered as two intramuscular injections and provides protection for up to six months.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy